Pharma Marking – Indian Pharmaceutical Companies And U.S. Border Tax

MLT CreativeIndustries

Recent news reports reveal that while India contributes nearly a third of the overall volume of drugs consumed in the U.S., domestic pharmaceutical companies in the country exporting drugs to the U.S. may be impacted by BAT, the border adjustment tax proposed under the Republican plan to revamp corporate taxes. According to reports, India exports approximately 40% of their overall …

Pharmaceutical Packaging – FDA Accepts BLA For MYL-1401O

MLT CreativeIndustries

Recently it was announced that the BLA (biologics license application) for a product purported as biosimilar to branded trastuzumab, and indicated to treat certain HER2-positive breast cancers, was accepted by the FDA. Mylan and Biocon submitted the BLA for MYL-1401O; its acceptance by the FDA is an important step forward for providing U.S. patients with this type of breast cancer …

Pharma Coding – FOSRx To Acquire Louisiana-Based F.A.S.T.

MLT CreativeIndustries

Recently it was revealed in a news release that Cumberland, MD based FOSRx (Factor One Source Pharmacy) would acquire F.A.S.T. (Fast Access Specialty Therapeutics) based in Metairie, LA through a combination of cash and stock. FOSRx, or Factor Once Source Pharmacy serves patients across the U.S., providing specialty prescriptions for those requiring specialized management of medications for chronic medical conditions. …

Pharma Coding – Corporation Lands Contract To Build Novo Nordisk Plant

MLT CreativeIndustries

Recently it was announced that Fluor Corporation of Irving, TX landed a $1.2 billion contract to design and build the $2 billion manufacturing facility for Novo Nordisk‘s diabetes API (Active Pharmaceutical Ingredient) in North Carolina. News reports reveal the world-class facility designed to provide diabetes patients with modern treatments is the largest investment in a life sciences facility in the …

Pharma Coding – Novo Nordisk Pledges To Put A Lid On Price Increases

MLT CreativeIndustries

Recently it was announced by Novo Nordisk U.S.‘ EVP, Jakob Riis, that the Denmark-based company pledges to limit increases in drug prices in the U.S., acknowledging the difficulty many patients with diabetes have when it comes to the ability to afford their medications. Riis said in an article posted on the Novo Nordisk A/S website that future increases in price …